MetaADEDB 2.0 @ LMMD
Acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
(YFDMUNOZURYOCP-XNHQSDQCSA-N)
Structure
SMILES
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1cnc[nH]1)Cc1cc2c([nH]1)cccc2)CO)Cc1ccc(cc1)O)CC(C)C)CC(C)C)CCCN=C(N)N
Molecular Formula:
C61H88N16O14
Molecular Weight:
1269.450
Log P:
3.4473
Hydrogen Bond Acceptor:
28
Hydrogen Bond Donor:
16
TPSA:
468.84
CAS Number(s):
N/A
Synonym(s)
1.
Acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
External Link(s)
PubChem Compound73415782
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1PainFAERS: 3US FAERS
2AnxietyFAERS: 2US FAERS
3DizzinessFAERS: 2US FAERS
4Drug ineffectiveFAERS: 2US FAERS
5FatigueFAERS: 2US FAERS
6Injection site painFAERS: 2US FAERS
7Mood swingsFAERS: 2US FAERS
8NauseaFAERS: 2US FAERS
9Abdominal PainFAERS: 1US FAERS
10Adenoidal disorderFAERS: 1US FAERS
11AdenoidectomyFAERS: 1US FAERS
12Angina PectorisFAERS: 1US FAERS
13ArthralgiaFAERS: 1US FAERS
14AsthmaFAERS: 1US FAERS
15Blood testosterone increasedFAERS: 1US FAERS
16Breast tendernessFAERS: 1US FAERS
17Central nervous system lesionFAERS: 1US FAERS
18Cold sweatFAERS: 1US FAERS
19Depressed moodFAERS: 1US FAERS
20DiscomfortFAERS: 1US FAERS
21Enzyme abnormalityFAERS: 1US FAERS
22Feeling abnormalFAERS: 1US FAERS
23FolliculitisFAERS: 1US FAERS
24HeadacheFAERS: 1US FAERS
25Incorrect dose administeredFAERS: 1US FAERS
26Incorrect route of drug administrationFAERS: 1US FAERS
27Injection site abscessFAERS: 1US FAERS
28Intentional product misuseFAERS: 1US FAERS
29Joint swellingFAERS: 1US FAERS
30Myocardial InfarctionFAERS: 1US FAERS
31Night sweatsFAERS: 1US FAERS
32Psychiatric symptomFAERS: 1US FAERS
33Therapeutic response unexpectedFAERS: 1US FAERS
34TonsillectomyFAERS: 1US FAERS
35TremorFAERS: 1US FAERS
36WheezingFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.